Last update 21 Dec 2024

TransCon IL-2 beta/gamma(Ascendis Pharma)

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
TransCon IL-2 β/γ - Ascendis Pharma
Target
Mechanism
IL-2R agonists(Interleukin-2 receptor agonists)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Head and Neck Squamous Cell CarcinomaPhase 2
US
29 Sep 2023
Advanced Head and Neck Squamous Cell CarcinomaPhase 2
GE
29 Sep 2023
Advanced Head and Neck Squamous Cell CarcinomaPhase 2
DE
29 Sep 2023
Advanced Head and Neck Squamous Cell CarcinomaPhase 2
HU
29 Sep 2023
Advanced Head and Neck Squamous Cell CarcinomaPhase 2
IT
29 Sep 2023
Advanced Head and Neck Squamous Cell CarcinomaPhase 2
PL
29 Sep 2023
Advanced Head and Neck Squamous Cell CarcinomaPhase 2
ES
29 Sep 2023
Advanced Head and Neck Squamous Cell CarcinomaPhase 2
TW
29 Sep 2023
Locally Advanced Head and Neck Squamous Cell CarcinomaPhase 2
US
29 Sep 2023
Locally Advanced Head and Neck Squamous Cell CarcinomaPhase 2
GE
29 Sep 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
-
xlmbzizxvu(mxdbjxofly) = pdqztwrhjo ppkyatvyce (reofepekye )
Positive
03 Jun 2024
TransCon IL-2 β/γ
(colorectal cancer)
tgertkyifm(pnogzwuppa) = oacaqzweoe euokjmlpjm (zlgpbhmxyf )
Phase 1/2
Solid tumor
absolute lymphocyte counts (ALC) | cytotoxic lymphocytes (CLs) | soluble CD25 ...
46
gploqrvdcm(smeymfovlh) = cmuizoxhsy mdrrwzzxnc (vzdpaefjus )
Positive
24 May 2024
gploqrvdcm(smeymfovlh) = lkmnwijsmm mdrrwzzxnc (vzdpaefjus )
Phase 1/2
39
TransCon IL-2 β/γ (20 to 160 mcg/kg)
hgvnxnulus(uqbqtgrgrw) = ozhxonpvwh rjkjtnbujm (pfyuiprxyg )
Positive
23 Oct 2023
hgvnxnulus(uqbqtgrgrw) = sgrkyhwenb rjkjtnbujm (pfyuiprxyg )
Phase 1/2
27
azqgqsdswb(qhuzmazwpx) = 1 Dose Limiting Toxicity of G3 CRS was reported at DL4. jnyxqzdfdw (dtdvnrusap )
Positive
31 May 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free